Iradimed (IRMD) Cost of Revenue (2013 - 2026)

Iradimed (IRMD) has 14 years of Cost of Revenue data on file, last reported at $4.1 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $4.1 million, down 13.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.8 million (down 1.41% YoY), and the FY2025 annual result was $17.4 million, up 3.13% from the prior year.
• Cost of Revenue eased to $4.1 million in Q1 2026 per IRMD's latest filing, from $4.6 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $6.6 million in Q4 2023 and troughed at $793716.0 in Q1 2023.
• A 5-year average of $3.9 million and a median of $4.1 million in 2026 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue tumbled 74.14% in 2023, then jumped 430.47% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $3.7 million in 2022, then soared by 79.84% to $6.6 million in 2023, then decreased by 12.11% to $5.8 million in 2024, then dropped by 20.53% to $4.6 million in 2025, then dropped by 11.98% to $4.1 million in 2026.
• Business Quant data shows IRMD's Cost of Revenue at $4.1 million in Q1 2026, $4.6 million in Q4 2025, and $4.7 million in Q3 2025.